Shanghai Pharmaceuticals Holding Co. Ltd. has described quinazoline compounds acting as TNF-α and/or IL-6 and/or IL-1β production inhibitors reported to be useful for the treatment of cancer, asthma, malaria, viral infections, autoimmune diseases, cardiovascular disorders, chronic obstructive pulmonary disease (COPD) and transplant rejection.